INNOVATION FOR THE FUTURE
F3 is working with a variety of clinicians and scientists from hospitals and universities to extend the use of NESDEP® IU into other areas as well, including bacterial meningitis and pseudomonas.
F3 offers incredibly valuable medical diagnostic capabilities. Our NESDEP® IU is in the process of securing 510K clearance from the US Food and Drug Administration (FDA) for the use of NESDEP® IU and related test kits for the detection of Methicillin-resistant Staphylococcus aureus (MRSA): a bacterium that cannot easily be treated with first-line antibiotics. MRSA creates havoc at hospitals because it can spread among sick patients and result in extended hospital stays or other complications that dramatically increase costs and may even result in death.
In the spring of 2013 the Haiti Program at the University of Notre Dame and F3 embarked upon a joint program to improve the diagnosis of Lymphatic Filariasis in human subjects. Lymphatic Filariasis is the cause of Elephantiasis, a painful and disfiguring disease that affects millions of people in the developing world. NESDEP® IU can detect this disease in the blood samples in about one hour.